SCHEMBL7122454

SCHEMBL7122454

CC(C)c1c(O)c2cc(Cl)ccc2[nH]c1=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 3/20 0.58
GRIN3B O60391 3/20 0.58
GRIN1 Q05586 3/20 0.58
GRIN2A Q12879 3/20 0.58
GRIN2B Q13224 3/20 0.58
GRIN2C Q14957 3/20 0.58
GRIN3A Q8TCU5 3/20 0.58
KDM4E B2RXH2 1/20 0.56
MEN1 O00255 2/20 0.52
MAPT P10636 2/20 0.52
KMT2A Q03164 2/20 0.52
ALDH1A1 P00352 1/20 0.52
SIRT1 Q96EB6 1/20 0.52
LMNA P02545 1/20 0.47
PTGS2 P35354 2/20 0.47
ABCC4 O15439 1/20 0.47
C5 P01031 1/20 0.47
PTGS1 P23219 1/20 0.47
PDE4D Q08499 1/20 0.47
DAO P14920 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7118635 0.86 GRIN2D (0.53) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL7114921 0.82 DAO (0.46) KDM4EMEN1MAPTKMT2AALDH1A1
SCHEMBL7120211 0.78 ALDH1A1 (0.62) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL3642320 0.78 KDM4E (0.62) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL13390923 0.77 CSF1R (0.65) KDM4EMAPTALDH1A1GSK3B
SCHEMBL404810 0.76 GRIN2D (0.63) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL23510959 0.76 GRIN2D (0.58) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL7114815 0.76 ALDH1A1 (0.67) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Hydrochloric Acid SCHEMBL440774 0.75 GRIN2D (0.61) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL11375916 0.74 KDM4E (0.61) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030069271-A1 Quinolone compounds for use in treating viral infections SMITHKLINE BEECHAM CORPORATION 2003-04-10 US disclosed
EP-1244629-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2002-10-02 EP disclosed
WO-2001046150-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069271-A1 Quinolone compounds for use in treating viral infections IRF3, MAVS, NQO2 GRIN2D 4621/4885GRIN3B 2718/4885GRIN1 2916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.